Geisinger

Geisinger Health Plan Policies and Procedure Manual

Policy: MP308 Wireless Pulmonary Artery Pressure Monitoring

Section: Medical Benefit Policy

Subject: Wireless Pulmonary Artery Pressure Monitoring

Applicable Lines of Business

Commercial	**X**	**CHIP**	**X**
Medicare	**X**	**ACA**	**X**
Medicaid	**X**		

I. Policy: Wireless Pulmonary Artery Pressure Monitoring

II. Purpose/Objective:

To provide a policy of coverage regarding Wireless Pulmonary Artery Pressure Monitoring

III. Responsibility:

A. Medical Directors
B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards of good medical treatment practiced by the general medical community.
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an

illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION:
This technology consists of a sensor implanted in the distal pulmonary artery, a transvenous delivery system, and an electronic processor that transmits pulmonary artery pressure measurements from the implanted sensor to a secure database. This technology includes, but is not limited to, the CardioMEMS™ Champion Heart Failure Monitoring System, the ImPressure® device, and the Chronicle® implantable continuous hemodynamic monitoring device.

The CardioMEMs HF System is a minimally invasive wireless heart failure remote monitor, placed in the pulmonary artery via femoral vein access, that has been clinically proven to significantly reduce heart failure hospitalizations and improve quality of life in New York Heart Association (NYHA) Class III patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

COMMERCIAL and NON-MEDICARE BUSINESS SEGMENT:
The CardioMEMs HF System is considered to be medically necessary in members who meet all of the following criteria:

- Diagnosis of New York Heart Association (NYHA) Class III heart failure with preserved ejection fraction; **or**
- Diagnosis of New York Heart Association (NYHA) Class III heart failure with reduced ejection fraction and on stable AHA/ACC guidelines based medical therapy

And

- At least one hospitalization for heart failure in the previous year.

MEDICARE BUSINESS SEGMENT:
Novitas LCD Outpatient Wireless Pulmonary Artery Pressure Monitoring for Heart Failure (L36419**)** has been retired. The CardioMEMs HF System is considered to be medically necessary in members diagnosed with New York Heart Association (NYHA) Class III heart failure with systolic or preserved ejection fraction who have been hospitalized for heart failure in the previous year.

EXCLUSIONS:
The Plan does NOT provide coverage for non-FDA approved usage of the device.

The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

Medicaid Business Segment:
Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Wireless Pulmonary Artery Pressure Monitoring
The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov ***or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.***

93799 Unlisted cardiovascular service or procedure [when specified as implantation of a wireless pressure sensor in the pulmonary artery]
33289 Transcatheter implantation of wireless pulmonary artery pressure sensor for long term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography

93264 Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional.
C2624 Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components

LINE OF BUSINESS:
Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:
Geisinger Technology Assessment Committee Triage Group. Implantable Wireless Pulmonary Artery Pressure Sensor. June 2016; Re-review July 2018

Abraham WT, Adamson PB, Bourge RC, et al.; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet. 2011; 377(9766):658-666.

Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomized trial. Lancet. 2015; pii: S0140-6736(15)00723-0

Horwitz, Leora, MD (July 2015) Strategies to reduce hospitalizations in patients with heart failure. UpToDate, Post TW (Ed), UpToDate, Waltham, MA.

Adamson PB, Abraham WT, Aaron M et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail 2011; 17(1):3-10.

Adamson PB, Gold MR, Bennett T et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients with Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail 2011; 17(5):248-54.

Krahnke JS, Abraham WT, Adamson PB, et al. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail. Mar 2015;21(3):240-249

Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED) -- CardioMEMS HF System. 2014. http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100045b.pdf.

Loh JP, Barbash IM, Waksman R. Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System. J Am Coll Cardiol 2013; 61(15):1571-6.

Benza RL, Raina A, Abraham WT, Adamson PB, Lindenfeld J, Miller AB, Bourge RC, Bauman J, Yadav J. Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor. J Heart Lung Transplant. 2015 Mar 1;34(3):329-37.

Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, Henderson J, Cowart P, Stevenson LW. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014 Nov 1;7(6):935-44.

Raval, N, Abraham, W, Adamson, P, Chronos, N, Sachar, R, and Ginn, G. Long-term effects of implantable hemodynamic monitoring in patients with moderate heart failure. European Heart Journal. 2011;32 Suppl. 1298

Feldman, D, Naka, Y, Cabuay, B, Takayama, H, Bauman, J, Cowart, P, Corcoran, K, Levy, W, and Moazami, N. A wireless hemodynamic pressure sensor before and after ventricular assist device placement: A sub-study of the CHAMPION Trial. Journal of Heart and Lung Transplantation. 2011;30(4 Suppl. 1):S86.

Local Coverage Determination (LCD): Outpatient Wireless Pulmonary Artery Pressure Monitoring for Heart Failure (L36419) https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=36419&ver=10&name=314*1&UpdatePeriod=671&bc=AQAAEAAAAAAAAA%3d%3d&

Zhou, S., Chen, P., Li, H., Zeng, C., Fang, Y., Shi, W., & Yang, C. Noninvasive measurement of cardiac output during 6-minute walk test by inert gas rebreathing to evaluate heart failure. Acta Cardiologica, 2016;71 (2), 199-203.

Schmier JK, Ong KL, Fonarow GC. Cost-effectiveness of remote cardiac monitoring with the CardioMEMS heart failure system. Clin Cardiol. 2017;40(7):430-436.

Heywood JT, Jermyn R, Shavelle D, et al. Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation. 2017;135(16):1509-1517

Winifred S. Hayes, Inc. Health Technology Brief. CardioMEMS implantable hemodynamic monitor (Abbott) for managing patients with heart failure. January 2019.

Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.

Shavelle DM, Desai AS, Abraham WT, et al. Pulmonary artery pressure-guided therapy for ambulatory heart failure patients in clinical practice: 1-year outcomes from the CardioMEMS post approval study. Presented at: ACC; March 17, 2019.

Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.

Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.

Jermyn R, Alam A, Kvasic J, Saeed O, Jorde U. Hemodynamic-guided heart-failure management using a wireless implantable sensor: Infrastructure, methods, and results in a community heart failure disease-management program. Clinical Cardiology. 2016.

Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69(19):2357-65.

Givertz MM, Stevenson LW, Costanzo MR, et al., on behalf of the CHAMPION Trial Investigators. Pulmonary artery pressure–guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70:1875-86.

Biederman RWW, Doyle M, Correa-Jaque P, et al. Integrated use of cardiac MRI and the CardioMEMS™ HF system in PAH: The utility of coincident pressure and volume in RV failure – The NHLBI-VITA Trial. Cardiovasc Diagn Ther. 2019;9(5):492-501.

Shavelle DM, Desai As, Abraham WT, et al; for the CardioMEMS Post-Approval Study Investigators. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: One-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail. 2020;13:e006863.

Angermann CE, Assmus B, Anker Sd, et al; for the MEMS-HF Investigators. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: The CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail. 2020 Jun 27

Salavitabar A, Bradley EA, Chisolm JL, et al. Implantable pulmonary artery pressure monitoring device in patients with palliated congenital heart disease: Technical considerations and procedural outcomes. Catheter Cardiovasc Interv 2020;95(2):270-279.

DeFilippis EM, Henderson J, Axsom KM, et al. Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice: A Sex-Specific Analysis of the CardioMEMS Post-Approval Study. Circ Heart Fail. Jun 2021; 14(6): e007892

Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. Sep 11 2021; 398(10304): 991-1001.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 8/16

Revised: 8/20 (add Medicare coverage); 11/20 (add Commercial coverage)

Reviewed: 10/17, 10/18**,** 10/19, 11/21, 11/22, 11/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at https://www.geisinger.org/health-plan/providers/ghp-clinical-policies